Loading post...
[Portfolio Weekly Report 2026-06-24]. Health Score: 4/10.
| Ticker | Sector | Entry Price (USD) | Latest Price (USD) | Unrealized Loss | Holding Period |
|---|---|---|---|---|---|
| INTC | Tech | $21.84 | $18.32 | -16.1% | ~7 months |
| QCOM | Tech | $168.50 | $142.15 | -15.6% | ~5 months |
| ASTS | Tech | $6.82 | $4.27 | -37.4% | ~14 months |
| NFLX | Tech | $920.00 | $638.50 | -30.6% | ~9 months |
| DD | Industrial | $82.40 | $71.85 | -12.8% | ~6 months |
| LMT | Industrial | $458.00 | $412.30 | -9.97% | ~4 months |
| SOFI | Financial | $12.10 | $7.83 | -35.3% | ~11 months |
| EDIT | Materials | $14.60 | $9.45 | -35.3% | ~8 months |
Total Unrealized P&L: ~ -21.3% (cost-weighted average), all 8 holdings in the red.
(Data source: Entry prices based on portfolio management records; latest prices sourced from public market data on 2026-06-24)
⚠️ Concentration Risk: Tech sector at 69%, exceeding the single-sector cap of 50%, leaving significant systemic risk exposure.
Tech holdings total 69%, nearly 19 percentage points above the portfolio's 50% cap. Under a market style dominated by the AI transition, such a high single-sector exposure means portfolio performance is heavily reliant on the tech market trend, lacking the ability to hedge against a tech pullback.
Current Status: Intel's Data Center and AI (DCAI) revenue for FY2025 was approximately $13.3B, down ~3% YoY; Q1 2026 continued to decline, with revenue of ~$2.9B, down ~11% YoY. Server CPU market share has been pressured by AMD's EPYC series, estimated to have fallen below 20% by end-2025 (peaked above 90%).
Causal Chain: Process node lag (Intel 7nm production delays) → widening generational performance gap → cloud vendors shifting orders to AMD/ARM → data center revenue shrinking → profit pressure forcing retrenchment strategy → stock price under pressure.
Trigger Conditions for Recovery: If Intel's 18A process achieves production breakthrough, or large government subsidy contracts (CHIPS Act) materialize, the competitive landscape could shift—but there is currently no clear timeline.
Current Status: QCOM's FY2026 Q1 earnings showed QCT (chip) revenue of ~$8.9B, down ~8% YoY; mobile chip business under pressure, with extended destocking cycles for high-end Android models. Data center (Snapdragon X series for AI PCs) revenue still below 5% of total, not yet at scale.
Causal Chain: Slowing global smartphone shipment growth (~1.21B units in 2025, +3% YoY, but longer replacement cycles for high-end models) → pressure on QCOM's high-end baseband demand → AI PC chips not yet ramping → overall revenue growth constrained → margin pressure.
Trigger Conditions for Recovery: If the AI PC market explodes early and Snapdragon X series secures major orders from top PC OEMs, a second growth curve may emerge—but current penetration is below 3%, and the timing window is unclear.
Current Status: DuPont has set aside ~$5.4B in reserves for PFAS-related litigation; Q1 2026 litigation costs were ~$320M, continuously eroding cash flow. In chemicals, FY2025 revenue was ~$14.3B, down ~6% YoY, dragged down by the cyclical downturn.
Causal Chain: Uncertainty over PFAS litigation settlement framework → continuous reserve funding → cash flow pressure → shareholder value erosion → valuation discount. Settlement negotiations are still ongoing in 2026, and the amount may expand further.
Trigger Conditions for Recovery: If the litigation settles for a fixed amount below market expectations, the valuation overhang could lift, leading to a stock price recovery—but the risk is that the settlement amount exceeds expectations.
Current Status: AST SpaceMobile is still in the satellite network deployment phase, with approximately 21 satellites in orbit as of June 2026 and a planned ~168 satellites. Commercial service is expected to launch in select regions in H2 2027; currently no revenue, cash flow negative.
Risk Structure:
Rationale for Holding: If bullish on the long-term satellite internet track, a 1-2 year catalyst vacuum must be accepted; if the goal is short-term optionality, there is currently no trigger.
Current Status: SoFi Technologies Q1 2026 revenue ~$210M, net loss ~$42M, not yet sustainably profitable. Deposits ~$23B, but deposit-taking costs are pressured by the high-rate environment, compressing spreads.
Risk Structure:
Current Status: Netflix Q1 2026 revenue ~$10.2B, +15% YoY; paid subscribers ~315M, growth driven mainly by ad-tier plans. Competitive landscape: Disney+, Max, etc., continue to vie for user engagement.
Key Points: Stock down ~30% from highs; current valuation has returned to relatively reasonable levels, but streaming penetration is near saturation, and ad-tier monetization efficiency remains to be seen.
Current Status: Editas Medicine's core pipeline EDIT-301 (hemoglobinopathies) is in Phase I/II clinical trials; no commercial products. Cash ~$280M as of Q1 2026 end, providing a runway of about 2 years at current burn rate.
Risks: If clinical results disappoint, stock price could be highly volatile; high dilution risk from financing.
The portfolio currently faces core issues:
Conclusion: The portfolio's overall health score is 4/10. Key risks include excessive tech concentration (69%), several holdings facing competitive or litigation pressure, and high-risk names lacking near-term catalysts. All positions are underwater with no reversal of the downtrend. It is recommended to prioritize reducing tech concentration, gradually trim names with clear negative catalysts, and add low-correlation sectors to achieve true diversification.